No prior studies have compared Tc-99m tilmanocept (TcTM) one-day and two-day injection protocols for sentinel lymph node (SLN) biopsy in breast cancer (BC). We retrospectively identified patients with clinically node-negative BC undergoing SLN biopsy at our institution. Patients received a single, intradermal peritumoral injection of TcTM on day of surgery or day prior to surgery in addition to an intraoperative injection of isosulfan blue dye. Univariable and multivariable Poisson regression count models were constructed to assess the effects of injection timing, radiologist, patient and surgeon characteristics on the number of removed SLNs. A total of 617 patients underwent SLN biopsy with TcTM and blue dye. Sixty-seven (10.9%) patients were injected with the two-day protocol. Patients in the one-day protocol had a mean of 3.0 (standard deviation (SD) 1.9) SLNs removed compared with 2.7 (SD 1.4) SLNs in the two-day protocol, P-value = .13. On multivariable analysis, patient age and operating surgeon significantly affected the number of removed SLNs; however, the injection timing and the nuclear radiologist did not influence the number of removed SLNs. The performance of Tc-99m tilmanocept did not differ significantly between one-day and two-day injection protocols. These results are similar to other radiotracers used for SLN biopsy in BC.
| INTRODUCTION
Tc-99m tilmanocept (Lymphoseek, Navidea Biopharmaceuticals, Dublin, OH) received initial FDA approval for lymphatic mapping in March 2013. 1 While prior studies have examined the timing on the use of Tc-99m sulphur colloid, [2] [3] [4] [5] Tc-99m nanocolloid, 6 Tc-99m
antimony sulphide colloid, 7 no prior studies have compared clinical outcomes of same day and day prior to surgery injection protocols of Tc-99m tilmanocept in breast cancer.
Tc-99m tilmanocept selectively binds to mannose receptors on dendritic cells and macrophages within lymph nodes on the cell surface marker CD206. 8, 9 The 7 nm diameter and homogeneity of tilmanocept allows for fast injection site clearance, and its specific binding in lymphatic tissue may facilitate sustained SLN uptake. 10, 11 As a result, varying the timing of Tc-99m tilmanocept injection may influence the number of SLNs a surgeon removes.
We sought to compare the number of removed SLNs between "one-day" and "two-day" Tc-99m tilmanocept injection protocols in axillary lymphatic mapping in breast cancer. Additionally, we sought to determine whether the injecting radiologist influenced the total number of removed SLNs. 
| ME TH ODS

| Radiopharmaceutical preparation
Tc-99m tilmanocept was prepared by a central radiopharmacy (Cardinal Health) according to manufacturer (Navidea Biopharmaceuticals, Dublin, OH) package insert. The agent was delivered in a single, 27-gauge tuberculin syringe to the hospital's Nuclear Medicine Department. Upon arrival, the agent was routinely surveyed for gamma activity by trained nuclear medicine technicians.
| Tc-99m tilmanocept injection
Injections were administered or supervised by one of three licensed Nuclear Medicine physicians. Per protocol, after confirming the correct patient and side for injection, the radiologist uses an alcohol wipe to clean off the patient's skin above the tumour. 
| Surgery
After induction of anaesthesia, one of two breast surgeons injected 2-3 mL of isosulfan blue dye intradermal or subcutaneous in the peritumoral vicinity. Intraoperatively, SLNs were determined by one of three criteria. A SLN was defined as radioactive "hot," "blue" and/or a palpably suspicious node. A radioactive "hot" node activity was measured by a portable gamma probe and had a count >3 times higher than background count. 
| Statistical methods
Baseline patient and technical characteristics between "one-day" and "two-day" protocols were assessed with t test for continuous vari- 
.2).
A P-value <.05 was used for statistical significance.
| RESULTS
A total of 668 patients received an injection of Tc-99m tilmanocept during the study period. Fifty-one patients did not meet inclusion criteria and were excluded (18-only received single agent injection, 23-had prior SLN biopsy or axillary node dissection and 10-had known node-positive disease prior to chemotherapy and attempt of SLN biopsy). We had 617 patients included in our retrospective analysis. At least one SLN was detected in 100% of patients. The overall mean number of removed SLNs was 2.98 (standard deviation [SD]
1.83). Ninety-five (15.4%) patients had ≥1 positive SLN. At least one radioactive "hot" node was identified in 609 (98.7%) patients and ≥1
"blue" node in 550 (89.1%) patients. Sixty-seven (10.9%) patients underwent injection with the "two-day" protocol. 
| DISCUSSION
Our data represent the largest clinical report on use of Tc-99m tilmanocept in breast cancer since FDA agent approval in March 2013.
Overall, a single intradermal injection of Tc-99m tilmanocept was detected surgically in the axilla of 98.7% of total patients undergoing dual-tracer SLN biopsy for breast cancer. Additionally, we found that neither the timing of Tc-99m tilmanocept injection nor the injecting nuclear radiologist influenced the number of axillary lymph nodes removed by surgeons during SLN biopsy. Our results are consistent with prior reports of other radiotracers demonstrating minimal or no statistical differences between one-day and two-day protocols for Tc-99m sulphur colloid, 4 Tc-99m nanocolloid 6 and Tc-99m antimony sulphide colloid. 7 Initially, we were concerned the small size and rapid injection site clearance 9 of tilmanocept may lead to fewer removed lymph nodes as time elapsed from initial injection. However, the CD206-specific tilmanocept receptor binding within the lymph nodes 10 facilitated consistent lymph node retention in the "two-day" protocol. These characteristics provide flexibility in patient scheduling. At our institution, patients are required to be injected with radiopharmaceuticals by a licensed nuclear medicine physician in the Nuclear Medicine Department, and scheduling "backups" occur around scheduled morning operations. However, we have found that injecting Tc-99m tilmanocept the day prior to surgery reduces Nuclear Medicine Department congestion and allows surgeons to start their cases earlier the following morning.
We have had success with a single, preoperative intradermal injection of Tc-99m tilmanocept overlying the tumour. Patients have reported less pain, 12 and we have consistent clinical outcomes. 13 While prior studies have shown the benefit of intradermal Tc-99m tracer injection 14 and the influence of surgeons performing intraoperative radiotracer injection, 15 to our knowledge, no prior study has examined the injecting radiologist as a covariate in surgical outcomes. With a single injection, we were concerned that the nuclear T A B L E 1 Patient characteristics "One-day" vs "Two-day" protocols Variables "One-day" " Two-day" P-value n = 550 n = 67 
| CONCLUSION
Injection of Tc-99m tilmanocept the day prior to surgery did not significantly alter the number of removed axillary sentinel lymph nodes in patients with clinically node-negative breast cancer. These results are similar to other radiotracers used for sentinel lymph node biopsy in breast cancer.
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